StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Entresto (sacubitril/valsartan by Quarter

Entresto (sacubitril/valsartan — chronic heart failure & hypertension) ($M)

QuarterlyAnnual

Novartis Entresto (sacubitril/valsartan: $1,165M in Q3 2026, down 37.9% from a year earlier.

Latest, Q3 2026
1,165
Period ended Sep 30, 2026
Change on a year earlier
-37.9%
1,877 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
29
Documents cited below

Where the Q3 2026 figure comes from

“|| Entresto | 1 165 | 1 877 | – 38 | – 38”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEntresto (sacubitril/valsartan — chronic heart failure & hypertension) ($M)Year on yearSource
Q3 2026Sep 30, 20261,165-37.9%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20261,181-49.9%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 20261,305-42.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20251,253-42.5%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20251,877+0.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20252,357+24.2%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 20252,261+20.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 20242,180+33.3%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20241,865+25.6%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 20241,898+25.2%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 20241,879+34.3%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 20231,635+26.6%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 20231,485+30.8%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 20231,516+34.8%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 20231,399+28.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 20221,291+36.0%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up entresto (sacubitril/valsartan

Cite this data

StockData. (2026). Novartis Entresto (sacubitril/valsartan ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-entresto

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.